학술논문
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Document Type
Article
Author
Source
In Annals of Oncology November 2009 20(11):1794-1802
Subject
Language
ISSN
0923-7534